Impel Neuropharma
Seattle, US · Delaware corporation · 5 known investors
Healthtech
Founders & leadership
JD
John D. HoekmanFounder
Board
MH
Michael HiteBoard director
SP
Stewart ParkerBoard director
Investors · 5
5AM VenturesBoston · $100K – $4M
.jpeg){kind=logo}
B Capital GroupreportedManhattan Beach · $10M – $50Mvia Robert Mittendorff · board
venBio Global StrategicreportedSan Francisco
venBio PartnersreportedSan Franciscovia Aaron Royston · board
Westlake Village BioPartnersreportedLos Angeles · $100K – $5Mvia David Allison · board
Reported raises · per SEC filings
Form D private placements$36.2M disclosed across 6 of 12 rounds · 2015–2021
▶$1.9MofferedApr 2021 · 1 investors · Other Health CareRule 506(b)
▶$1.9MofferedApr 2021 · 1 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- John LeamanExecutive Officer
- Aaron RoystonDirector
- John D. HoekmanExecutive Officer, Director
- Ali SatvatDirector
- Adrian AdamsExecutive Officer, Director
- David AllisonDirector
- Mahendra ShahDirector
- Diane WilfongDirector
- Robert MittendorffDirector
- Tim NelsonDirector
- Stewart ParkerDirector
- Offering amount
- $1.9M
- First sale
- Mar 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7.5MraisedMar 2021 · 8 investors · Other Health CareRule 506(b)
▶$7.5MraisedMar 2021 · 8 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Robert MittendorffDirector
- Tim NelsonDirector
- Ali SatvatDirector
- John LeamanExecutive Officer
- Diane WilfongDirector
- Adrian AdamsExecutive Officer, Director
- John D. HoekmanExecutive Officer, Director
- Stewart ParkerDirector
- Aaron RoystonDirector
- Mahendra ShahDirector
- David AllisonDirector
- Offering amount
- $7.5M
- Amount sold
- $7.5M
- First sale
- Mar 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$490KofferedFeb 2021 · 2 investors · Other Health CareRule 506(b)
▶$490KofferedFeb 2021 · 2 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- John D. HoekmanExecutive Officer, Director
- Stewart ParkerDirector
- Aaron RoystonDirector
- Mahendra ShahDirector
- David AllisonDirector
- Adrian AdamsExecutive Officer, Director
- Tim NelsonDirector
- Ali SatvatDirector
- John LeamanExecutive Officer
- Diane WilfongDirector
- Robert MittendorffDirector
- Offering amount
- $490K
- First sale
- Feb 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.6MofferedMay 2020 · 1 investors · Other Health CareRule 506(b)
▶$5.6MofferedMay 2020 · 1 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- John D. HoekmanExecutive Officer, Director
- Aaron RoystonDirector
- Adrian AdamsExecutive Officer, Director
- Stewart ParkerDirector
- Diane WilfongDirector
- Tim NelsonDirector
- David AllisonDirector
- Ali SatvatDirector
- Mahendra ShahDirector
- Robert MittendorffDirector
- John LeamanExecutive Officer
- Offering amount
- $5.6M
- First sale
- May 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$481.5KofferedJan 2020 · 1 investors · Other Health CareRule 506(b)
▶$481.5KofferedJan 2020 · 1 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Aaron RoystonDirector
- Adrian AdamsDirector
- Diane WilfongDirector
- John LeamanExecutive Officer
- Ali SatvatDirector
- Tim NelsonDirector
- Robert MittendorffDirector
- Jon CongletonExecutive Officer, Director
- David AllisonDirector
- Mahendra ShahDirector
- Stewart ParkerDirector
- John D. HoekmanExecutive Officer, Director
- Offering amount
- $481.5K
- First sale
- Jan 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.6MofferedJul 2019 · 1 investors · Other Health CareRule 506(b)
▶$1.6MofferedJul 2019 · 1 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Tim NelsonDirector
- John LeamanExecutive Officer
- Ali SatvatDirector
- Robert MittendorffDirector
- Jon CongletonExecutive Officer, Director
- David AllisonDirector
- Mahendra ShahDirector
- Aaron RoystonDirector
- John D. HoekmanExecutive Officer, Director
- Stewart ParkerDirector
- Offering amount
- $1.6M
- First sale
- Jun 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.4MofferedFeb 2019 · 4 investors · Other Health CareRule 506(b)
▶$1.4MofferedFeb 2019 · 4 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Mahendra ShahDirector
- Stewart ParkerDirector
- Aaron RoystonDirector
- Robert MittendorffDirector
- Ali SatvatDirector
- John D. HoekmanExecutive Officer, Director
- Tim NelsonDirector
- Jon CongletonExecutive Officer, Director
- Jim YoungDirector
- Offering amount
- $1.4M
- First sale
- Feb 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$22.3MraisedDec 2016 · 10 investors · Other Health CareRule 506(b)
▶$22.3MraisedDec 2016 · 10 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Jim YoungDirector
- Stewart ParkerDirector
- Mahendra ShahDirector
- Aaron RoystonDirector
- John D. HoekmanExecutive Officer, Director
- Offering amount
- $37.3M
- Amount sold
- $22.3M
- Sales commissions
- $1M
- Finders' fees
- $2.5K
- Placement agents
- Cascadia Capital, LLC
- First sale
- Nov 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 6 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2016 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2013 | $675.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $149.5K |
| Department of DefenseOffice for Chemical and Biological Defense | Phase II | 2011 | $749.6K |
| Department of DefenseOffice for Chemical and Biological Defense | Phase I | 2010 | $98.3K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2009 | $495.2K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- Who founded Impel Neuropharma?
- Impel Neuropharma was founded by John D. Hoekman.
- Who are Impel Neuropharma's investors?
- Impel Neuropharma's investors include 5AM Ventures, B Capital Group, venBio Global Strategic, venBio Partners, Westlake Village BioPartners.
- How much funding has Impel Neuropharma raised?
- Impel Neuropharma has disclosed $36.2M raised across 6 of its 12 known rounds.
- Where is Impel Neuropharma headquartered?
- Impel Neuropharma is headquartered in Seattle, US.